13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Xetra |
90,510 |
05.06.24 17:35:52 |
-0,020 |
-0,02% |
0,000 |
0,000 |
90,920 |
90,530 |
|
Regeneron Pharmaceuticals |
881535 |
NASDAQ |
1.009,800 |
05.06.24 21:33:05 |
+16,510 |
+1,66% |
1.009,110 |
1.011,110 |
989,790 |
993,290 |